Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Meningeal Carcinomatosis 1

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × omburtamab I-131 × Clear all
NCT03275402 2024-02-13

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Y-mAbs Therapeutics

Phase 2/3 Terminated
52 enrolled 11 charts
CNS

Neuroblastoma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡